All In Biotech

Drug Trial Radar · NCT04742634

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

209

Planned (sponsor's estimate)

Start

May 12, 2022

Primary completion

Nov 30, 2033

Study completion Nov 30, 2033

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Taiho Oncology, Inc.
First posted
Feb 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • DEC-CDrug

    * DEC-C will be provided by Taiho Pharmaceuticals. * Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.

  • MyeloSeq-HDDevice

    -Laboratory test developed at Washington University School of Medicine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with dose-limiting toxicities (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
  2. Maximum tolerated dose (MTD) (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
  3. Recommended phase II dose (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
  4. Progression-free survival (PFS) (Phase II recommended dose only)Time frame: 1 year post-transplant
  5. Rate of relapse (Phase II recommended dose only)Time frame: 1 year post-transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.